With a market capitalization (market cap) of $24.54B — a measure of how much the company is worth — Incyte Corporation ranks #519 among the 2,416 companies tracked, and 66th in Healthcare as of November 17, 2026. Shares trade at $120.38, up 0.05% on the day.
As of November 17, 2026 · Prices may be delayed
of 2,416 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 13, 2026. The headline market cap is from the ranking update on November 17, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 13, 2026 | $24.59B | +24.87% | $120.97 |
| 2025 | Dec 31, 2025 | $19.69B | +47.16% | $98.77 |
| 2024 | Dec 31, 2024 | $13.38B | -4.97% | $69.07 |
| 2023 | Dec 29, 2023 | $14.08B | -21.26% | $62.79 |
Ranking figure $24.54B as of November 17, 2026.
Market cap = share price × shares outstanding.
Incyte Corporation's ranking market cap is the reported market cap from the latest ranking update, with a share price of $119.55 as of November 17, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $24.59B on November 13, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 195,204,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $119.55. The headline price of $120.38 is from the ranking update on Nov 17, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.33T | -1.18% |
| #20 | Johnson & Johnson JNJ | $673.59B | -0.98% |
| #23 |
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 17, 2026, Incyte Corporation (INCY) is worth $24.54B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Incyte Corporation’s book equity is about $5.17B. Market cap is the market value of the outstanding shares. As of November 17, 2026, its market cap is $24.54B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Incyte Corporation ranks #519 among the 2,416 companies tracked on MarketCapLens. In Healthcare it ranks #66 of 350.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
| 2022 | Dec 30, 2022 | $17.88B | +10.07% | $80.32 |
|---|
| 2021 | Dec 31, 2021 | $16.25B | — | $73.40 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
FY 2025
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $517.75B |
| -0.60% |
| #30 | UnitedHealth Group Incorporated UNH | $354.98B | -3.92% |
| #31 | Merck & Co., Inc. MRK | $354.79B | -0.39% |
| #37 | Novartis AG NVS | $301.28B | -0.42% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #516 | Expeditors International of Washington, Inc. EXPD | $24.68B | -2.17% |
| #517 | United Therapeutics Corporation UTHR | $24.61B | -1.72% |
| #518 | Axon Enterprise, Inc. AXON | $24.55B | -1.59% |
| #520 | Constellation Brands, Inc. STZ | $24.51B | -1.22% |
| #521 | TechnipFMC plc FTI | $24.45B | -1.41% |
| #522 | Baidu, Inc. BIDU | $24.4B | -3.16% |
Incyte Corporation’s ranking market cap of $24.54B comes from the same snapshot as the rest of this site, as of November 17, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 195,204,000. The historical market-cap series last observed $24.59B on November 13, 2026.
Over the past year, Incyte Corporation’s market cap is up 18.14%, using historical market-cap records rather than today’s share count applied to past prices.
Incyte Corporation (INCY) shares trade at $120.38, up 0.05% on the day, as of November 17, 2026.
Incyte Corporation trades at a live price-to-earnings (P/E) ratio of 18.1, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.